Multiple Myeloma - Current Treatment - Treatment Sequencing - Multiple Myeloma (US)

Key benefits and uses

Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.

Identify untapped treatment scenarios and key competitors to aid trial design.

Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.

Discover untapped populations to expand product share and drive strategic decisions.

QUESTIONS ANSWERED

Where is my product positioned versus competitors in the treatment journey?
What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
What are the market-relevant treatment scenarios according to oncology experts?
Where are the untapped business opportunities on which I can capitalize?
How can I optimize trial design and ensure a competitive edge for my pipeline asset?

GEOGRAPHY

United States

PRIMARY MARKET RESEARCH

Survey of 102 U.S. hematologist-oncologists

Product description

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts’ assumptions.

Multiple Myeloma - Current Treatment - Treatment Sequencing - Multiple Myeloma (US)
- Treatment Sequencing Multiple Myeloma US August 2023
- Treatment Sequencing Multiple myeloma US August 2023

Contact sales account_box

Report

Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)

First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…

north_east

Report

Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)

Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…

north_east

Report

Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)

Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…

north_east

Report

Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)

Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…

north_east

Report

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…

north_east

Product logins

Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)

Table of contents

Related Market Assessment Reports

Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)

Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)

Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)

Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

Follow us

Contact us